Daniel Bronder's questions to Ascendis Pharma A/S (ASND) leadership • Q2 2025
Question
Daniel Bronder of Cantor Fitzgerald, on for Lee Watsak, asked about patient compliance and pull-through for Yorvipath and sought clarification that the reported 1,500 patient figure represented net new patient starts.
Answer
President & CEO Jan Møller Mikkelsen cited long-term data from Europe showing an extremely low true discontinuation rate of only a few percent, which he attributed to the significant therapeutic benefit. He also confirmed that the enrollment figures refer to unique new patient prescriptions.